We focused on the diagnosis of CTRCD by the end of treatment, as this can affect ongoing cancer treatment and majority of CTRCD events in women with HER2+ early-stage breast cancer occur by the end of the treatment [4,11,18,24]. Here, ERBB2 is linked to cancer.